ReviewExperimental and therapeutic medicine2019
Therapeutic options in patients with biochemical recurrence after radical prostatectomy.
Review in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio (NLR) and Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) for Biochemical Recurrence After Radical Prostatectomy.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Development of a Risk Model to Identify and Prevent Factors Influencing Erectile Dysfunction After Robotic Radical Prostatectomy.Journal of clinical medicine · 2025Article
- Research progress on surgical factors related to early urinary control after laparoscopic radical prostatectomy.American journal of clinical and experimental urology · 2023Review
- Renal replacement therapy in cancer patients with acute kidney injury (Review).Experimental and therapeutic medicine · 2021Review
- Multiple sclerosis, human herpesvirus 4 and thyroid collision tumor: A case report.Experimental and therapeutic medicine · 2020Article
- Benefits of erectile function recovery programs after radical prostatectomy (Review).Experimental and therapeutic medicine · 2020Review
- Highlights of the 3rd conference of the Romanian Association of Immuno-Dermatology and the 37th conference of the Romanian Society of Immunology held in Bucharest between September 19 and 22, 2019.Experimental and therapeutic medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the second most common form of cancer in men in Europe. The primary treatment of this type of cancer is radical prostatectomy, which has shown good oncological results. Radical prostatectomy (open, laparoscopic or robotic) has high success and low morbidity rates in patients with localized prostate cancer. The life expectancy is >10 years after radical prostatectomy. Studies have shown that ~20%-30% of the patients who have undergone radical prostatectomy can develop biochemical recurrence, which is monitored by using the value of the prostate-specific antigen (PSA). In some cases (patients with high-risk prostate cancer), adjuvant therapy after radical prostatectomy, such as radiotherapy or androgen deprivation therapy, can significantly reduce the risk of biochemical recurrence. The optimal management of recurrent disease remains uncertain. Recent literature was systematically reviewed regarding the management of biochemical recurrence and to compare clinical experience in literature studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.